ArticlePsychological medicine2026
Antidepressant effect of transcranial pulse stimulation (TPS) targeting neuropsychiatric disorders: a retrospective analysis.
Article in Psychological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prefrontal Transcranial Pulse Stimulation for Major Depressive Disorder: A Randomized Clinical Trial.JAMA network open · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundDepression is a common comorbidity in neuropsychiatric disorders, affecting a significant proportion of patients with neurodegenerative diseases. Traditional antidepressants show limited efficacy, particularly in cases involving comorbid depressive symptoms, highlighting the need for alternative treatments.
methodsHere we provide the first data on possible benefits of add-on therapy with transcranial pulse stimulation (TPS). Based on the largest patient sample in the emerging field of focused ultrasound (FUS) neuromodulation to date, a retrospective analysis was conducted on 88 patients with various neuropsychiatric diagnoses to evaluate the impact of TPS on depressive symptoms, measured by the Beck Depression Inventory (BDI-II).
resultsThe study revealed significant improvements in BDI-II scores posttreatment (
conclusionsThe study's findings indicate that TPS enhances depression outcomes in neuropsychiatric patients, particularly in those with more severe depressive symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.